We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Comments on FDA’s Opioid Risk-Benefit Guidance Highlight Misuse
Comments on FDA’s Opioid Risk-Benefit Guidance Highlight Misuse
Syneos Health offered some suggestions for the FDA’s draft guidance for drugmakers on assessing the risks and benefits of opioids, urging the agency to highlight prior opioid exposure, guidance on tapering use and proper disposal.